Farallon Capital Management LLC decreased its holdings in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Free Report) by 2.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 325,000 shares of the company’s stock after selling 7,000 shares during the […]
Reata Pharmaceuticals (NASDAQ:RETA) Receives Neutral Rating from Cantor Fitzgerald themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Reata Pharmaceuticals (NASDAQ:RETA) Earns Neutral Rating from Cantor Fitzgerald theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Free Report) has received a consensus recommendation of “Hold” from the thirteen analysts that are presently covering the company, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among […]
Barclays downgraded shares of Reata Pharmaceuticals (NASDAQ:RETA – Free Report) from an overweight rating to an equal weight rating in a research report released on Tuesday, MarketBeat reports. Barclays currently has $172.00 price target on the stock, up from their previous price target of $110.00. Several other equities analysts also recently weighed in on RETA. […]